In COPD, muscular atrophy is a significant risk factor for death and may prolong patients’ hospital length of stay.

In acute infective exacerbation of chronic bronchitis or chronic obstructive pulmonary disease (COPD), adding erdosteine to standard treatment significantly modified the outcome by improving the ...

Vantage Market Research is pleased to announce the publication of its latest report, Asthma and COPD Drugs Market. This ...

The effect of erdosteine on mucus rheological properties was evaluated in patients with exacerbation of COPD. [24] Patients receiving erdosteine had statistically significant reduction in sputum ...

Researchers from the European Molecular Biology Laboratory have found that dextromethorphan, a common cough syrup ingredient, can potentially treat pu ...

Insilico Medicine, a clinical-stage biotechnology company pioneering generative AI for drug discovery and development, ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...

Swimming in Lakes Linked to Legionnaires’ Disease Risk, Study WarnsSwimming in some lakes with still water can lead to infection with Legionella, ...

“Following the exacerbation of bronchitis in recent days, the Holy Father has undergone specialist examinations and started pharmacological therapy in ... he had part of one lung removed after a ...

Gemelli' Polyclinic Foundation — revealed the onset of bilateral pneumonia, requiring additional pharmacological therapy," stated ... of one of his lungs removed when he was young due to a pulmonary ...

ISM001-055 was shown to have attenuated cellular senescence through the suppression of various aging processes, thus showing potential as a senomorphic drug.